Cerebrolysin Treatment for Broca's Aphasia After Stroke
Author Information
Author(s): Jianu DC, Muresanu DF, Bajenaru O, Popescu BO, Deme SM, Moessler H, Meinzingen SZ, Petrica L, Serpe M, Ursoniu S
Primary Institution: ‘Victor Babes’ University of Medicine and Pharmacy, Clinical Emergency County Hospital, Timisoara, Romania
Hypothesis
The study aimed to assess the efficacy of Cerebrolysin administration in Broca's aphasics with acute ischemic stroke.
Conclusion
Cerebrolysin is effective for the treatment of Broca's aphasics with a first acute ischemic stroke of the left MCA territory.
Supporting Evidence
- The Cerebrolysin group showed significant improvement in language function compared to the placebo group.
- Both treatment groups had similar demographics and baseline characteristics.
- The mortality rate was the same in both groups at 90 days.
- Cerebrolysin was well tolerated with no significant adverse effects compared to placebo.
- Patients in the Cerebrolysin group had a higher frequency of favorable outcomes at 90 days.
Takeaway
Cerebrolysin helps people who have trouble speaking after a stroke get better at talking again.
Methodology
The study involved a randomized clinical trial with 2,212 Broca's aphasics, where 52 received Cerebrolysin and 104 received a placebo, with language evaluated over 90 days.
Potential Biases
Assessors were not blinded to treatment allocation, which may have influenced outcomes.
Limitations
The study had a wide treatment time window and used conventional MRI instead of more sensitive diffusion-weighted imaging.
Participant Demographics
Patients were right-handed Broca's aphasics aged 20-75 years with acute left MCA ischemic stroke.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website